The properties of control and 370Asn-->Ser glucocerebrosidase, the frequently encountered mutated form of the enzyme in type 1 Gaucher disease, were studied in vitro as well as in situ. The catalytic properties of purified 370Asn-->Ser glucocerebrosidase were highly dependent on the assay conditions. The enzyme was deficient in activity towards substrate and in reactivity with the irreversible inhibitor conduritol B-epoxide (CBE) when activated by the bile salt taurocholate. In the presence of more physiological activators, the lysosomal activator protein saposin C and phosphatidylserine, the 370Asn-->Ser enzyme was near normal in kinetic properties at pH values approximately 5, but not at higher pH. In intact fibroblasts, the enzymic activity of the 370Asn-->Ser glucocerebrosidase and its reactivity with CBE were found to be clearly deficient. However, in intact lymphoblasts from the same patients, the behavior of the mutant enzyme was near normal. The catalytic efficiency of 370Asn-->Ser glucocerebrosidase in situ was also found to be highly pH dependent. When intact lymphoblasts were cultured in the presence of permeant weak bases, which increase the pH of acidic intracellular compartments, the catalytic efficiency of the mutant enzyme, as assessed by its reactivity with CBE, became markedly impaired. Our findings indicate that the intralysosomal pH in the intact cell can be expected to have a critical influence on the activation state of 370Asn-->Ser glucocerebrosidase and 
Introduction
Gaucher disease (glucosylceramidosis) is a recessively inherited lysosomal storage disorder in which the activity of glucocerebrosidase (EC 3.2.1.45) is deficient. The clinical mani-festation ofthe disease is very heterogeneous with respect to age of onset and neurological involvement. In patients with the most frequently encountered form, type 1, the clinical presentation may vary from cases with severe splenomegaly and bone deterioration to cases without clear clinical complications ( 1). Type 2 and type 3 Gaucher disease patients develop neurological complications in infancy or childhood, respectively ( 1). Gaucher disease is genetically heterogeneous. Several mutations in glucocerebrosidase have been identified (2) (3) (4) (5) (6) , and it has become clear that patients may have either two identical or, more generally, two different mutant glucocerebrosidase alleles (see e.g., references 7 and 8) . Most type 1 Gaucher disease patients carry at least one copy of a mutant glucocerebrosidase allele in which a mutation at position 1,226 in the cDNA leads to substitution of G for A (cDNA nucleotides are numbered starting with the upstream ATG at number 1 [9] ). This results in a substitution ofserine for asparagine at amino acid position 370 in the mature protein (8, 10, 11 ) . The 370Asn --Ser glucocerebrosidase is present in normal amounts (12) (13) (14) (15) . In vitro, this enzyme is only poorly active under most conditions; however, when activated at acidic pH by negatively charged phospholipid and the natural lysosomal activator protein saposin C, formerly referred to as sphingolipid activator protein 2 (for a review, see reference 16), its activity is near normal ( 17) . Another frequently encountered form of mutated glucocerebrosidase has a C for T substitution at nucleotide position 1,448, resulting in a proline for leucine substitution at position 444 in the mature protein. This mutation has been detected in various phenotypes of Gaucher disease. Most patients who are homozygous for this mutation develop a neuronopathic course ofthe disease (7, 11, (18) (19) (20) . The 4"Leu -* Pro glucocerebrosidase results in reduced enzyme stability (15) (16) (17) (18) (19) (20) (21) . In a third commonly encountered allele, a G insertion in the glucocerebrosidase gene at cDNA position 84 results in production of a truncated protein (22) .
The consequences ofthe 370Asn -o Ser substitution for catalytic efficiency of glucocerebrosidase in situ are not yet fully understood. It has previously been observed by us that the state of activation of 370Asn
Ser glucocerebrosidase, and concomitantly its catalytic efficiency, differs in homogenates of fibroblasts and lymphoblasts obtained from the same type 1 Gaucher disease patients (23) . We have now studied the properties of glucocerebrosidase in intact fibroblasts and lymphoblasts. First, the degradation ofa fluorescent analogue ofglucocerebroside by intact cells was measured. Second, the reactivity of glucocerebrosidase with the irreversible inhibitor conduritol B-epoxide (CBE)' was assessed. This inhibitor is analogous in structure to the transition state of gluconolactone formed during hydrolysis of glucocerebroside. In contrast to the natural transition state compound, the epoxide is able to form a covalent bond with an aspartic acid group in the catalytic site, thus irreversibly inhibiting the enzyme (2, 24) . It has elegantly been shown by Bieberich and Legler (25) that CBE rapidly enters lysosomes in intact cells and effectively inhibits the enzyme in situ.
Our investigation revealed differences between properties ofglucocerebrosidase in intact fibroblasts and in intact lymphoblasts from type 1 Gaucher disease patients with 370Asn --Ser glucocerebrosidase. The possible role of the natural activator protein saposin C and lysosomal pH in this connection was investigated. The results are reported here, and the implications are discussed. Ser, "4Leu -* Pro/44Leu --Pro and 370Asn -* Ser/4"Leu -* Pro.
Methods
Fibroblasts were obtained by skin biopsies and lymphoblasts were obtained by transformation of peripheral blood B lymphocytes with EBV (23, 26) . The cells were cultured in RPMI 1640 containing 10% (by volume) FCS and bicarbonate with 5% CO2 in the gas phase. The glucocerebrosidase genotype of the patients was determined by allelespecific oligonucleotide hybridization (26) . In the case of patient C (Table I) , it has not as yet been excluded that the mutated 44Leu -* Pro allele contains additional mutations (also referred to as complex pattern alleles). The cell biological consequences of the 44Leu -0 Pro mutation and one of the complex pattern alleles are known to be similar; i.e. the production of a rapidly degraded glucocerebrosidase ( 15) .
The Gaucher disease patients homozygous or heterozygous for the 370Asn --Ser allele varied markedly in severity of nonneuronopathic manifestation of the disorder. The patients homozygous for the 44Leu --Pro allele had developed neurological complications already in infancy (type 2) or only in childhood (type 3).
Consistent with earlier findings, it was noted using PAGE in the presence of sodium dodecyl sulphate followed by Western blotting (27) , that the amount of glucocerebrosidase antigen was normal in fibroblasts ofpatients homozygous for the 370Asn --Ser allele (i.e., type 1 patients) and very strongly reduced in fibroblasts of patients homozygous for the 44Leu --Pro allele (i.e., type 2 and 3 patients). In cells from patients who were genetic compounds carrying both alleles, intermediate amounts of cross-reactive glucocerebrosidase were detected. Preparation of antisera. A monospecific rabbit antiserum to human placental glucocerebrosidase was prepared as described (28) . A monospecific rabbit antiserum to saposin C was prepared as described (29) .
Immunoaffinity chromatographic purification of glucocerebrosidase. Glucocerebrosidase was purified from various materials by immunoaffinity chromatography with immobilized antiglucocerebrosidase monoclonal antibodies 8E4 and 2C7 as immunosorbens exactly as described previously (30). Purification of saposin C. The activator protein was purified according to the procedure described (31) .
Assessment ofactivator protein level. The level of activator protein was determined by a functional test as described (12) . (12, 13, 15) . Thus, identical amounts of various types ofglucocerebrosidase will be bound to a specific amount of immobilized monoclonal antibody 8E4 when the immunosorbens is saturated by incubation with an excess of an enzyme preparation. If the enzyme preparation consists of a mixture of two forms of glucocerebrosidase, the bound glucocerebrosidase will be a comparable mixture. These binding characteristics of the monoclonal antibody 8E4 allow a simple analysis of the specific activity of mutated glucocerebrosidase per amount of enzyme protein as described previously ( 12) . Briefly, identical amounts ofantiglucocerebrosidase monoclonal antibody 8E4 were immobilized to wells of a microtiter plate. The wells were incubated with enzyme preparations containing an excess of glucocerebrosidase antigen. The activity of bound glucocerebrosidase was measured with the fluorogenic 4-MU-3-glucoside as substrate as described in the legend ofTable I. Fluorescence in the wells of the microtiter plate was determined (Fluoroscan; Flow Laboratories Inc., McLean, VA) with excitation at 366 nm and emission at 450 nm.
Measurement ofhydrolysis of C6-NBD glucosylceramide in intact cells. C6-NBD glucosylceramide was complexed with BSA as described (13) . Cells were incubated for 24 h at 370C with 5 juM lipid-BSA complex in the absence or presence of excess CBE. The cells were harvested, and lipids were extracted and separated by thin layer chromatography. The fluorescent lipids were scraped off, extracted, and quantified fluorimetrically as described ( 13) .
Immuno-electron microscopy. Cultured human skin fibroblasts and EBV-lymphoblasts were fixed and prepared for immunogold labeling and electron microscopy following the procedure described for fibroblasts (33) . Frozen cell samples were cryosectioned and immunolabeled, and examined using a transmission electron microscope (model 300; Phillips Electronic Instruments Co., Mahwah, NJ) at an accelerating voltage of 60 kV.
Results

Enzymic properties ofpurified glucocerebrosidase
Glucocerebrosidase was purified by immunoaffinity chromatography from cultured skin fibroblasts. The recovery of enzyme in monomeric form (31 ) was always > 70% on the basis of enzymic activity as measured in the presence of taurocholate.
Relative specific activity. The enzymic activity per amount of cross-reactive glucocerebrosidase related to that of control enzyme (i.e., the relative specific activity) was determined for enzyme preparations from fibroblasts from various types of Gaucher disease patients (see Table I ). When measured in the presence oftaurocholate and Triton X-100, the relative specific activity of glucocerebrosidase in preparations of cells of patients homozygous for the 370Asn --Ser allele is abnormally low, and that of enzyme in preparations from cells of patients homozygous for the "4Leu -> Pro allele is close to normal. The relative specific activity of glucocerebrosidase in preparations from cells of patients who are genetic compounds for the 370Asn --Ser and "4Leu Pro alleles is also low, suggesting that they contain predominantly 370Asn --Ser glucocerebrosidase molecules.
When bound glucocerebrosidase is measured in the presence of phosphatidylserine and activator protein the relative specific activity of enzyme in the preparations from fibroblasts of all the patients is near normal (see Table I ). In other words, under these conditions, the "70Asn -* Ser glucocerebrosidase is normalized.
The amount ofcross-reactive glucocerebrosidase can be estimated by comparing the data for relative specific activity with values for specific activity in the corresponding cell extracts. In this way, it was calculated that the concentration of glucocerebrosidase antigen is 80-100% in fibroblasts from patients with genotype 370Asn -. Ser/370Asn -* Ser, < 10% in cells from patients with genotype "4Leu --Pro/444Leu --Pro and -30% in cells from patients carrying both alleles.
Inactivation by CBE. The irreversible inhibition of glucocerebrosidase by CBE was determined for enzyme purified from fibroblasts of individuals with different glucocerebrosidase genotypes. Fig. 1 A shows the results when enzyme preparations were incubated with inhibitor in the presence of taurocholate and Triton X-100, and enzyme activity was subsequently determined under the same conditions. The glucocerebrosidase purified from fibroblasts of the patient homozygous for the "4Leu -* Pro allele was inactivated in a manner similar to control enzyme, but the inactivation of enzyme purified from cells of the patient homozygous for the 370Asn -* Ser allele was very slow. The inactivation of enzyme purified from cells of the genetic compound proceeded with intermediate kinetics. When the enzyme preparations were incubated with inhibitor in the presence ofphosphatidylserine and activator protein at pH 5.0, and the enzyme activity was determined under the same condition a different picture was obtained (see Fig. 1 B) . Under these conditions, the behavior of glucocerebrosidase purified from fibroblasts of all the Gaucher disease patients was not clearly different from that of control enzyme. This suggests that in the presence ofphospholipid and activator protein the 370Asn -* Ser glucocerebrosidase is not only 'normalized' in activity towards substrate, but also in reactivity with CBE.
Analogous findings to the results presented in Table I and served between enzyme preparations from the various sources examined.
It is of importance to note that the reactivity of glucocerebrosidase with CBE is to some extent a good reflection of the activity of the enzyme towards substrate. This was also observed when membrane suspensions were tested instead of pure enzyme preparations.
Enzymic properties ofglucocerebrosidase in intact fibroblasts and lymphoblasts Activity towards substrate. The glucocerebrosidase activity in cultured fibroblasts and lymphoblasts from type 1 Gaucher disease patients and control subjects was determined by loading cells with C6-NBD glucosylceramide as described in Methods. Recently we established the existence of a nonlysosomal glucocerebrosidase activity in cells that is insensitive to CBE. The properties of the nonlysosomal glucocerebrosidase, which is not deficient in Gaucher disease materials, are to be described in a separate publication. To allow discrimination between the lysosomal (CBE-sensitive) and nonlysosomal (CBEinsensitive) glucocerebrosidase cells were pretreated with and without an excess of CBE. The lysosomal glucocerebrosidase activity was determined as the CBE-inhibitable hydrolysis of C6-NBD glucosylceramide (Table II) . The residual activity in fibroblasts of patients with the 370Asn -* Ser allele was always less than that in lymphoblasts from the same patients.
Inactivation by CBE. The kinetics ofthe irreversible inhibition of glucocerebrosidase upon incubation of intact cells with CBE was examined (Fig. 2) . Glucocerebrosidase in control fibroblasts and in "4Leu --Pro/"4Leu -> Pro fibroblasts was clearly inactivated more rapidly than the enzyme in 370Asn -> Ser/370Asn -> Ser fibroblasts when enzyme activity was subsequently measured either in the presence of taurocholate and Triton X-100 (Fig. 2 A) or in the presence of phosphatidylserine and activator protein at acid pH (Fig. 2 B) . In 370Asn -o Ser/44Leu -> Pro fibroblasts, the inactivation ofglucocerebrosidase appeared to be more rapid when the activity was subsequently measured in the presence of taurocholate and Triton X-100 (Fig. 2 A) than when it was measured with phosphatidylserine and activator protein (Fig. 2 B) . This apparent discrepancy results from the fact that with activator protein and phosphatidylserine, one measures predominantly 370Asn --Ser enzyme, which is slowly inactivated, whereas in the presence of taurocholate and Triton X-100, 44Leu -> Pro enzyme contributes significantly to the total activity.
Comparison ofdiferent cell types. Cultured fibroblasts and lymphoblasts were incubated with CBE for different periods of time, and subsequently, enzymic activity ofglucocerebrosidase was measured in the presence of taurocholate and Triton X-l00. Table III shows again that lysosomal glucocerebrosidase in intact fibroblasts from patients with the 370Asn --Ser allele was clearly less sensitive to inhibition by CBE compared to enzyme in corresponding cells of a control subject and a patient homozygous for the 44Leu -> Pro glucocerebrosidase allele. However, glucocerebrosidase in cultured lymphoblasts from a control subject, a patient homozygous for the codon 370 substitution, and a patient with both the codon 370 and codon 444 substitutions was comparably inactivated by CBE. This celltype-specific difference between fibroblasts and lymphoblasts was also observed in three type 1 Gaucher disease patients with one allele with the codon 370 mutation and an as yet unidentified mutated allele (not shown).
Immunocytochemical analysis ofglucocerebrosidase and activator protein saposin C in cultured cells
The apparent difference in glucocerebrosidase activity in intact lymphoblasts and fibroblasts could, in principle, be caused by a relatively higher concentration of activator protein in lysosomes of lymphoblasts. To test this possibility, the relative intralysosomal concentrations of glucocerebrosidase and activator protein in fibroblasts and lymphoblasts were studied by immunoelectron microscopy using specific antisera. Fig. 3 shows some examples of double-labeling ofglucocerebrosidase and saposin in lysosomes in fibroblasts and lymphoblasts from Effect ofpH on activity of3'0Asn -* Ser glucocerebrosidase
Pure enzyme. The influence ofpH on enzymic activity ofpurified splenic 370Asn -> Ser glucocerebrosidase and control enzyme was studied using acetate and citric acid/sodium phosphate buffers in the pH range 4.0-6.0. Fig. 4 (not shown; see also [17] ). It appears that the 370Asn -) Ser substitution in glucocerebrosidase leads to an increased pH dependency of the enzyme with respect to activation by activator protein. Particularly at higher pH values, the mutated enzyme is poorly activated by saposin. Fig. 4 B shows that also the reactivity of 370Asn -* Ser glucocerebrosidase with CBE is extraordinarily pH dependent in the presence ofactivator protein and phospholipid. At higher pH values, the mutated enzyme is dramatically less sensitive for CBE-induced inactivation compared to control enzyme. Similar results to those presented in Fig. 4 were obtained with enzyme isolated from fibroblasts and lymphoblasts from patients homozygous for the 370Asn Ser allele. Furthermore, 370Asn --Ser glucocerebrosidase isolated from 3T3 fibroblasts transfected with site-directed mutagenized human glucocerebrosidase cDNA ( 15) showed a comparable pH dependency (not shown).
Manipulation ofintralysosomalpH with weak bases. Intact fibroblasts and lymphoblasts were exposed to NH4Cl, a weak base, to increase the intralysosomal pH, as described by Ohkuma and Poole (34) . These authors have shown that in mouse macrophages addition of increasing concentrations of NH4Cl leads to a concomitant increase in pH of intracellular acidic compartments (including lysosomes), as monitored by the extent of quenching of the fluorescence of endocytosed dextran-fluorescein isothiocyanate. For instance, on addition of 10 mM NH4Cl, the pH of such compartments increases from -4.8 to -6.2. Fig. 5 shows that with increasing amounts of NH4Cl, glucocerebrosidase in cells becomes less sensitive to inactivation by CBE, as would be expected from the results of Fig. 4 B. This effect of NH4Cl is reversible (not shown). It should be noted that in the absence ofNH4Cl glucocerebrosidase is much more effectively inactivated by CBE in Gaucher disease lymphoblasts than in Gaucher disease fibroblasts. However, at increasing concentrations of NH4C1, the rate of inactivation of glucocerebrosidase in lymphoblasts resembles that in fibroblasts from the same Gaucher disease patient. Similar observations were made using methylamine (not shown). The findings presented in Figs. 4 and 5 suggest that the intralysosomal pH to which glucocerebrosidase is exposed might on the average be lower in cultured lymphoblasts than in fibroblasts. As an approximate measure ofthe pH in lysosomes (and other acidic compartments), we measured the accumulation of radioactively labeled weak base chloroquine (35) . We observed that about seven times more radioactively labeled chloroquine was trapped by lymphoblasts than by fibroblasts when related to the amount of glucocerebrosidase present in the two cell types, whereas the immunogold labeling studies suggest that the concentration of glucocerebrosidase is about twice as high in lysosomes of fibroblasts than of lymphoblasts (see Table IV ). This suggests that the average intralysosomal pH is higher in fibroblasts than in lymphoblasts.
Assessment ofactivation state ofglucocerebrosidase. When control cells are homogenized in detergent-free buffer, a pro- [23] ). The bile salt abolishes any original activation ofglucocerebrosidase and activates fully all enzymes present (23) . Table VI shows that the activity in the absence of activator is relatively higher in a homogenate of lymphoblasts than that in a homogenate of fibroblasts. When the cells are pretreated with NH4C1 to increase the pH of intracellular acidic compartments (see above), this difference disappears and glucocerebrosidase is only poorly active in the absence of additional activator in homogenates from both cell types. This finding supports the assumption that on the average, glucocerebrosidase is present in a more activated state in intact lymphoblasts than in fibroblasts because of an intralysosomal pH difference.
Some of our findings are consistent with those of earlier studies. First, it has been reported by Grabowski and co- workers (36, 37) that the mutant form ofglucocerebrosidase in Ashkenazi Jewish type 1 Gaucher disease patients referred to as group B mutant enzyme is less efficiently inactivated by CBE than control enzyme either in fibroblast extracts or in partially purified splenic preparations. It is now almost certain that group B mutant enzyme is identical to the 370Asn --Ser glucocerebrosidase (2). Second, it has been reported that glucocerebrosidase in intact fibroblasts from Ashkenazi Jewish Gaucher disease type 1 patients was less efficiently inactivated by CBE compared to enzyme in cells from control subjects and from other Gaucher disease patients (36) . Thus, in the studies cited above, particular stress was laid upon the ethnic background of type 1 Gaucher disease patients. We have found that the rate of inactivation of glucocerebrosidase by CBE in fibroblasts from
Discussion
The properties of the 370Asn --Ser glucocerebrosidase in vitro are intriguing: Under most assay conditions, this mutated enzyme is impaired in activity towards substrate. However, in the presence of the natural activator protein saposin C and phosphatidylserine, the enzyme functions in a near normal fashion at an appropriate acidic pH. To obtain information on the properties ofthis mutated enzyme in situ, the irreversible inhibitor CBE has been used, an approach that was developed and used previously by other investigators (25, 36, 37) . Although it is obvious that the reaction of glucocerebrosidase with CBE involves only part of the total reaction mechanism of substrate hydrolysis (discussed in more detail in [2 ] ), analysis of CBEinduced inactivation of glucocerebrosidase is informative because the reactivity of (mutant) glucocerebrosidase with CBE appears to reflect to a large extent the ability of enzyme to be active towards substrate. Cell extracts were boiled for 5 min, centrifuged, and the supernatants were tested for their capacity to stimulate the enzymic activity of purified placental glucocerebrosidase as described (12) . 1 U of activation is defined as the amount of activator protein that stimulates the activity of glucocerebrosidase by a factor of 100. glucocerebrosidase, the catalytic properties of which are so strongly determined by the state of activation of the enzyme. Our studies suggest that the intralysosomal pH determines the state of activation of glucocerebrosidase. Again, this is particularly relevant for 370Asn -* Ser glucocerebrosidase: the activation of this mutant enzyme by activator protein is extraordinarily pH sensitive. Thus, a cell-type-specific difference in intralysosomal pH could explain the difference in properties of 370Asn -Ser glucocerebrosidase in intact fibroblasts and lymphoblasts. Moreover, variability between individuals in intralysosomal conditions may underlie the heterogeneity in severity of the clinical expression of Gaucher disease in individuals with the same glucocerebrosidase genotype. In this connection, it is of interest to mention that some homozygotes for the 370Asn -> Ser glucocerebrosidase mutation are not or only very mildly affected clinically (8, 38) 
